A Potential Therapeutic Effect of Suxiao Jiuxin Pills in Treating Postacute Sequelae of COVID‐19: Case Report

Postacute Sequelae of COVID‐19 Cardiovascular Syndrome (PASC‐CVS) refers to a broad spectrum of cardiovascular symptoms that manifest four weeks or more after infection with COVID‐19, which cannot be diagnosed as cardiovascular disease through standard examinations. Common symptoms include exercise intolerance and tachycardia, alongside persistent issues such as chest pain, chest tightness, and difficulty breathing. PASC‐CVS significantly affects patients’ quality of life; however, effective treatments for this condition are currently lacking. In this report, we present two cases of PASC‐CVS patients who experienced well‐controlled cardiovascular symptoms following treatment with Suxiao Jiuxin Pills. Our findings may offer a novel approach to the clinical management of PASC‐CVS.